O
OncoQuest
Combinatorial immunotherapy antibodies for cancer treatment
About OncoQuest
OncoQuest is a private, clinical-stage biotechnology company founded in 2015 and headquartered in Edmonton, Canada. The company specializes in the development and commercialization of combinatorial immunotherapy products designed for cancer treatment. It operates as a subsidiary of Quest PharmaTech Inc., a Canadian biotechnology firm traded on the TSX Venture Exchange.
The company's core business revolves around a portfolio of immuno-modulatory and tumor antigen-specific monoclonal antibodies. OncoQuest's primary strategy is to explore the therapeutic effects of its antibodies when used in combination with other immune-modulating drugs, chemotherapy, or targeted therapies to improve tumor-specific immunity and clinical results. The antibody portfolio targets various tumorigenic proteins, including CA-125, MUC1, PSA, and Her2/neu. Its lead product candidate is oregovomab, an antibody for treating ovarian cancer. Clinical trials have been conducted to evaluate oregovomab in combination with standard chemotherapy regimens like paclitaxel and carboplatin. The FLORA-5 Phase 3 study is a double-blind, placebo-controlled trial comparing chemo-immunotherapy (including oregovomab) against chemotherapy alone in patients with advanced ovarian cancer.
Dr. Madi Madiyalakan serves as the Chief Executive Officer. His extensive background includes founding and executive roles at several other biotechnology firms, such as SonoLight Pharmaceuticals, CanBiocin Inc., and AltaRex Corp. In April 2020, OncoQuest announced a definitive agreement to sell its drug portfolio to OncoQuest Pharmaceuticals Inc. (formerly Dual Industrial Co., Ltd.), a company listed in Korea, in a deal involving bonds and a commitment to fund the Phase 3 clinical trial for oregovomab. The company has received funding from investors including Hepalink USA and DUAL Co.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Edmonton, Canada
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 26.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, Start Alberta, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2020 | $50M | $200M | Undisclosed | ↗ |
| EARLY VCOther financing | Feb 2018 | $7.5M | $30M | Hepalink | — |
Growth signals
Latest recorded traffic for OncoQuest is 150 monthly website visits, down 11.8% over the last three months. OncoQuest's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Hepalink
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about OncoQuest on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OncoQuest’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.